At Ignyta, we fight cancer - a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, our vision is not just to shrink tumors but to eradicate residual disease - the source of cancer relapse and recurrence - in precisely defined patient populations by 2030. We will work tirelessly to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight.
For information on Ignyta’s STARTRK-2 clinical trial
of entrectinib, an investigational pan-Trk, ROS1, and ALK inhibitor, as the treatment of certain cancers visit www.startrktrials.com